カテゴリ： GlobalData, アメリカ, 企業調査

Portola Pharmaceuticals Inc (PTLA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Portola Pharmaceuticals Inc (PTLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10083
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company’s products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc (PTLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12
Partnerships 13
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16
Aciex Amends Research Agreement With Portola Pharma 17
Portola Pharma Expand Agreement with Lee’s Pharma 18
Licensing Agreements 19
Portola Pharma Enters into Licensing Agreement with SRX Cardio 19
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21
Equity Offering 23
Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23
Portola Pharma Prices Public Offering of Shares for USD150 Million 25
Portola Pharma Prices Public Offering of Shares for USD100 Million 27
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29
Portola Pharma Completes Public Offering Of Shares For US$106 Million 31
Portola Pharma Completes IPO For US$140 Million 32
Portola Pharmaceuticals Inc – Key Competitors 34
Portola Pharmaceuticals Inc – Key Employees 35
Portola Pharmaceuticals Inc – Locations And Subsidiaries 36
Head Office 36
Recent Developments 37
Financial Announcements 37
Nov 07, 2018: Portola Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 37
Aug 09, 2018: Portola Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 39
May 09, 2018: Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 40
Feb 28, 2018: Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 42
Nov 06, 2017: Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 44
Aug 09, 2017: Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 45
May 08, 2017: Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 46
Feb 28, 2017: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 47
Corporate Communications 49
Sep 20, 2018: Portola Pharmaceuticals appoints Scott Garland President and Chief Executive Officer 49
Sep 07, 2018: Portola Pharmaceuticals announces resignation of Tao Fu as chief commercial officer 50
Aug 09, 2018: Portola Pharmaceuticals appoints Ernie Meyer as executive vice president and chief human resources officer 51
Jun 25, 2018: Portola Pharmaceuticals Names Glenn Brame as Senior Vice President of Technical Operations 52
Jun 04, 2018: Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018 53
Mar 12, 2018: Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel 54
Nov 06, 2017: Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President and Chief Medical Officer 55
Product News 56
11/30/2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting 56
Product Approvals 57
Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma 57
Clinical Trials 58
Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib 58
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 60
Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 61
Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 62
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 63
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 64
Other Significant Developments 65
Oct 09, 2018: Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16
Aciex Amends Research Agreement With Portola Pharma 17
Portola Pharma Expand Agreement with Lee’s Pharma 18
Portola Pharma Enters into Licensing Agreement with SRX Cardio 19
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21
Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23
Portola Pharma Prices Public Offering of Shares for USD150 Million 25
Portola Pharma Prices Public Offering of Shares for USD100 Million 27
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29
Portola Pharma Completes Public Offering Of Shares For US$106 Million 31
Portola Pharma Completes IPO For US$140 Million 32
Portola Pharmaceuticals Inc, Key Competitors 34
Portola Pharmaceuticals Inc, Key Employees 35

List of Figures
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Portola Pharmaceuticals Inc (PTLA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Iberdrola, S.A.：企業の戦略・SWOT・財務情報
    Iberdrola, S.A. - Strategy, SWOT and Corporate Finance Report Summary Iberdrola, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Blackbird Energy Inc (BBI)：企業の財務・戦略的SWOT分析
    Summary Blackbird Energy Inc (Blackbird Energy), formerly Blackbird Investments Inc, is an independent oil and gas exploration and development company that acquires, explores, produces and develops oil and gas properties in Western Canada. The company holds interests in Elmworth Project which concen …
  • Airgas, Inc.：企業のM&A・事業提携・投資動向
    Airgas, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Airgas, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Bharti Infratel Ltd
    Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Micro Labs Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Micro Labs Ltd (Micro Labs) is a healthcare service organization which conducts research and development of bio equivalent generics. The organization’s business segments include formulations and active pharmaceutical ingredients. Its products include acetamide, allercet, amiodar, amlong, aml …
  • Black Hills Corp (BKH)：石油・ガス：M&Aディール及び事業提携情報
    Summary Black Hills Corp (BHC) is a vertically-integrated energy company which offers electricity and natural gas. The company produces, transmits, and distributes electricity; and sells natural gas on retail and wholesale basis. It generates electricity from natural gas, coal, diesel oil, and wind …
  • Rex Energy Corp (REXX)：石油・ガス：M&Aディール及び事業提携情報
    Summary Rex Energy Corp (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds properties in Appalachian Basin. Rex Energy focuses on drilling and exploration activities in th …
  • Holland Board of Public Works：企業の戦略的SWOT分析
    Holland Board of Public Works - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • DexCom Inc (DXCM)：企業の製品パイプライン分析
    Summary Dexcom Inc (Dexcom) is a medical device company that designs, develops and commercializes continuous glucose monitoring (CGM) systems. The company’s major products include integrated CGM systems for adults and pediatric use, Dexcom G5 mobile CGM system, Dexcom G4 PLATINUM CGM system, associa …
  • Blue Cross and Blue Shield Association：企業の戦略的SWOT分析
    Blue Cross and Blue Shield Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Entia Biosciences Inc (ERGO)：企業の財務・戦略的SWOT分析
    Summary Entia Biosciences Inc (EBI) is a biotechnology company that provides nutrigenomics solutions for organic health, beauty and agriculture. The company’s solution includes ErgoD2, mushroom dietary supplement, and multi joint support. It offers ErgoD2 solutions such as Ergo-D2-Hemo, Ergo-D2-FLEX …
  • TransAlta Corporation：企業の戦略・SWOT・財務情報
    TransAlta Corporation - Strategy, SWOT and Corporate Finance Report Summary TransAlta Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BBVA：企業のM&A・事業提携・投資動向
    BBVA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BBVA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings …
  • NovaBay Pharmaceuticals Inc (NBY)-製薬・医療分野：企業M&A・提携分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene …
  • Acer Incorporated：企業の戦略・SWOT・財務情報
    Acer Incorporated - Strategy, SWOT and Corporate Finance Report Summary Acer Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Orica Ltd：企業の戦略・SWOT・財務分析
    Orica Ltd - Strategy, SWOT and Corporate Finance Report Summary Orica Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Intuity Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Intuity Medical Inc (Intuity Medical), formerly Rosedale Medical is a medical device company that designs and develops medical devices to monitor diabetes. The company offers products such as POGO, an automatic blood glucose monitoring system; and Patterns, a web based data management system …
  • Oceanteam ASA (OTS)：企業の財務・戦略的SWOT分析
    Oceanteam ASA (OTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Lloyds Banking Group Plc：企業の戦略・SWOT・財務情報
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tox Free Solutions Limited (TOX)：企業の財務・戦略的SWOT分析
    Tox Free Solutions Limited (TOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆